CClinicalTrials.gg
Status unknownNCT01546805Updated Mar 7, 2012

Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm

An interventional study of Zinc Supplement and Sugar pill in Blepharospasm and Hemifacial Spasm, sponsored by St. Joseph's Healthcare Hamilton. Status unknown at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-07.

Sponsored by St. Joseph's Healthcare Hamilton · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2012), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether zinc supplements are effective in enhancing the treatment of oculofacial spasm disorders with botulinum toxin.

Read the detailed description

Botulinum Toxin (Botox) has been used for many years in the treatment of oculofacial dystonias such as blepharospasm and hemifacial spasm. It has also gained widespread use for cosmetic purposes. The efficacy and duration of its effect is not constant amongst all patients. Some patient respond very well, while others have no clinical benefit or the clinical benefit does not last as long as expected. Zinc is known to be an important co-factor in the molecular effects of Botox. The investigators hypothesize that one of the many factors that may contribute to the variability in the response to Botox may be the level of Zinc available within the neuromuscular junction of those patients. The investigators plan to to test whether or not giving patients supplemental Zinc with their Botox injections would help improve the magnitude and duration of the intended clinical effect.

02

Conditions studied

  • Blepharospasm
  • Hemifacial Spasm

Keywords

  • Blepharospasm
  • Hemifacial spasm
  • Botox
  • Zinc
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • greater than the age 18 years old
  • patient with hemifacial spasm
  • patient with benign essential blepharospasm.

Exclusion criteria

Exclusion Criteria:

  • patients who have received Botox within 3 months time,
  • patients prone to malabsorption (i.e. those with Celiac disease, inflammatory bowel disease, liver disease, laxative use)
  • patients who cannot tolerate zinc supplementation due to kidney disease, gastrointestinal disease, or any other medical condition.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Sugar pill

  • Experimental
    Zinc Group

    Drug: Zinc Supplement

Interventions

  • DrugZinc Supplement

    The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.

  • DrugSugar pill

    The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.

05

What researchers measure

Primary outcomes

  1. Jankovic Rating Scale

    a well established scale used in the literature to grade the symptoms of patients with facial spasms disorders.

    Time frame: 3 months post Botox injection

Secondary outcomes

  1. Treatment Duration Cycle

    The number of days between the date of Botox injection to the date in which the symptoms have returned back to baseline.

    Time frame: The time frame will vary with each patient. The time frame is in fact the outcome measure being measured. On average the Botox treatment cycles last 3 months, however this average may be affected by zinc supplements.

  2. Blepharospasm Disability Index (BDI)

    BDI is a scale commonly used in the Blepharospasm literature to measure the magnitude of the burden of symptoms in patients with Blepharospasm. It has also been used to measure treatment effect by a reduction in patient's BDI.

    Time frame: 3 months post Botox injection

06

Study locations

2 sites
  • St Joseph's Hospital Hamilton
    Hamilton, Ontario L8N4A6, Canada
  • Carrot Eye Centre
    Mississauga, Ontario L5J 2Y2, Canada
    • Yasser Khan, MD · Contact · 905-822-2020
    • Yasser Khan, MD · Principal investigator
07

Registry details

Key details

Study ID
NCT01546805
Lead sponsor
St. Joseph's Healthcare Hamilton
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Apr 2012
Primary completion
Dec 2012 (estimated)
Completion
Mar 2013 (estimated)
Last update
Mar 7, 2012

Study contacts

Gamal Seif, MD
Contact
gamal.seif@medportal.ca
9054073882
John Harvey, MD
Contact
jtharvey@mcmaster.ca
905-573-4848
John Harvey, MD
principal investigator · St Joseph's Hospital Hamilton
Yasser Khan, MD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion